Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlaxoSmithKline Pharmaceuticals Ltd.

http://www.gsk-india.com

Latest From GlaxoSmithKline Pharmaceuticals Ltd.

BMS/bluebird’s Ide-Cel: EU Decision Time On First CAR-T For Multiple Myeloma

The European Medicines Agency will decide this week whether BMS and bluebird bio’s cell-based gene therapy for multiple myeloma should be approved for use in the EU. 

Europe Drug Review

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include three new products, including GlaxoSmithKline's Jemperli (dostarlimab), which is the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. 

Approvals Europe

Pharma Execs Jumping Onboard Private Equity Train

More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.

India Commercial

GSK Sells Indian Site To Hetero Labs

GSK has sold its Vemgal manufacturing plant to Indian company Hetero Labs. GSK’s decision came after the recall of ranitidine products made in India.

India BioPharmaceutical
See All

Company Information

UsernamePublicRestriction

Register